Why outcome measurement matters
Sacroiliac joint radiofrequency ablation targets the posterior sacral network (PSN), including the lateral branches of S1–S3 and contributions from S4 and the L5 dorsal ramus, to interrupt nociceptive input from the sacroiliac joint complex. Consistent and rigorous outcome measurement is essential to determine whether this percutaneous radiofrequency ablation meaningfully reduces pain and disability in carefully selected patients with sacroiliac joint complex pain. The COBRA-SIJ trial was designed specifically to compare two commonly used radiofrequency strategies—Nimbus-based bipolar palisade lesions (N-SIJRFA) and conventional monopolar periforaminal lesions (C-SIJRFA)—using standardized outcome instruments over a 24‑month period.
Prior systematic review work in sacroiliac joint radiofrequency has shown that a substantial proportion of patients can achieve at least 50% pain relief at six months after posterior sacral network ablation, but reported success rates vary widely. This variability has been attributed in part to heterogeneous radiofrequency techniques and technologies used across studies, as well as differences in patient selection. The COBRA-SIJ protocol explicitly acknowledges this gap and frames its primary and secondary outcomes to capture pain, function, health-related quality of life, and global patient-reported change in a uniform manner, allowing more reliable comparison between bipolar strip-lesion and conventional monopolar approaches.
The choice of outcome measures in the COBRA-SIJ study reflects a deliberate effort to align clinical endpoints with domains that are most relevant to patients and clinicians. Pain intensity is captured with the Numeric Pain Rating Scale (NPRS), disability with the Oswestry Disability Index (ODI), health status with the EuroQol 5 Dimensions (EQ‑5D), and global improvement with the Patient Global Impression of Change (PGIC). These instruments are collected at baseline and at multiple follow-up time points up to 24 months, enabling assessment of both early and sustained treatment effects. In addition, the protocol includes measures of pain-related sleep disturbance and interventional health care utilization, providing a broader view of clinical impact beyond pain scores alone.
From a methodological standpoint, clearly defined responder thresholds are central to interpreting clinical outcomes after sacroiliac radiofrequency. The COBRA-SIJ trial defines its primary endpoint as the proportion of participants achieving at least a 50% reduction in NPRS pain score at three months, with secondary endpoints including the proportion achieving a 15‑point or greater reduction in ODI and a 0.03 or greater improvement in EQ‑5D. These thresholds are chosen to reflect clinically meaningful change and are incorporated into power calculations and survival analyses that examine time to failure, defined as return of at least 50% index pain or need for repeat sacroiliac radiofrequency ablation. This structured approach to outcome measurement is intended to clarify what constitutes treatment success and to support evidence-based expectations for patients undergoing sacroiliac radiofrequency.
Pain relief metrics (NPRS)
Pain intensity in the COBRA-SIJ study is quantified using the Numeric Pain Rating Scale (NPRS), a 0–10 scale capturing the average low back pain over the preceding seven days. At baseline, participants must report a seven‑day average NPRS of at least 4/10 to qualify for inclusion, ensuring that the cohort has clinically significant pain attributable to the sacroiliac joint complex. This baseline NPRS is then used as the reference point for evaluating relative changes in pain following radiofrequency ablation of the posterior sacral network.
The primary pain outcome in COBRA-SIJ is a responder analysis at three months, defined as the proportion of participants achieving at least a 50% reduction in NPRS compared with baseline. This 50% or greater threshold is used consistently across follow-up intervals and is also embedded in the trial’s statistical planning. Power calculations assume a control responder rate of 36% at six months and are designed to detect a 25‑percentage‑point relative increase in responders in the comparator arm, with adequate power to conclude superiority if the responder rate in the treatment group exceeds 61%. This framework underscores the central role of NPRS-based responder status in interpreting the clinical effectiveness of sacroiliac radiofrequency.
Beyond the three‑month primary endpoint, NPRS is collected longitudinally at 6, 12, 18, and 24 months to characterize the durability of pain relief after sacroiliac radiofrequency. Secondary outcomes include the proportion of participants with 50% or greater pain relief at each of these time points, as well as time to failure, defined as return of at least 50% of the index pain or the need for repeat sacroiliac radiofrequency ablation. This allows the investigators to construct survival analyses that depict the percentage of patients in each treatment arm who maintain treatment success without additional interventional procedures over two years.
NPRS is also used in the COBRA-SIJ protocol to guide decisions about repeat procedures. Repeat radiofrequency ablation is permitted after the six‑month outcome collection if the treating physician deems it indicated and the participant has demonstrated more than 50% improvement from baseline NPRS at earlier follow-up assessments. In this way, NPRS functions not only as a research endpoint but also as a pragmatic clinical tool for determining whether the initial sacroiliac radiofrequency provided sufficient benefit to justify re‑intervention. Together, these design elements illustrate how NPRS-based metrics structure expectations around pain relief trajectories after sacroiliac radiofrequency in the COBRA-SIJ framework.
Functional improvement (ODI, EQ-5D)
Functional outcomes are a key focus of the COBRA-SIJ study, reflecting the recognition that reductions in pain should translate into improved daily function and health-related quality of life. The Oswestry Disability Index (ODI) is used to quantify disability related to low back pain, with baseline ODI scores collected at the initial visit prior to radiofrequency ablation. The trial’s specific aims include comparing the proportion of participants in each treatment arm who achieve at least a 15‑point reduction in ODI, a threshold selected to represent clinically meaningful functional improvement. ODI is assessed at 3, 6, 12, 18, and 24 months, allowing evaluation of both early and sustained changes in disability following sacroiliac radiofrequency.
In parallel, the COBRA-SIJ protocol incorporates the EuroQol 5 Dimensions (EQ‑5D) instrument to capture broader health status and quality of life. Baseline EQ‑5D scores are obtained at enrollment, and follow-up assessments occur at the same intervals as ODI. A clinically significant improvement on EQ‑5D is defined as an increase of at least 0.03 in the index score, and one of the secondary outcomes is the proportion of patients in each group who meet or exceed this threshold at each follow-up time point. This dual focus on ODI and EQ‑5D provides complementary perspectives on functional recovery, with ODI emphasizing back pain–specific disability and EQ‑5D reflecting overall health-related quality of life.
The integration of ODI and EQ‑5D into the COBRA-SIJ outcome framework is closely linked to the trial’s central hypothesis that Nimbus-based bipolar palisade lesions will be more effective than conventional monopolar periforaminal lesions in improving both pain and function. By specifying responder thresholds for ODI and EQ‑5D, the investigators can directly compare the functional impact of the two radiofrequency strategies over time. These measures also facilitate interpretation of the clinical relevance of NPRS changes, as improvements in pain that are accompanied by meaningful gains in disability and quality of life are more likely to be considered successful from a patient-centered perspective.
Beyond their role as standalone endpoints, ODI and EQ‑5D are used in COBRA-SIJ to explore relationships between pain relief, functional improvement, and other clinical variables. One of the trial’s aims is to evaluate differences in success rates for pain improvement, functional improvement, and satisfaction among participants who experience varying degrees of pain relief (50% or greater, 80% or greater, and 100%) after prognostic posterior sacral network blocks or intra-articular sacroiliac joint injections. This design allows examination of whether greater reductions in pain are associated with higher probabilities of achieving substantial ODI and EQ‑5D gains, thereby informing expectations about functional outcomes after sacroiliac radiofrequency in patients with different baseline and prognostic profiles.
Patient satisfaction (PGIC)
The COBRA-SIJ study incorporates the Patient Global Impression of Change (PGIC) scale to capture patient-reported satisfaction and perceived overall improvement following sacroiliac radiofrequency ablation. PGIC is a categorical measure in which participants rate their global change since treatment, and the trial focuses on the proportions of patients who describe themselves as improved or much improved. This outcome is assessed at 3, 6, 12, 18, and 24 months, providing a longitudinal view of how patients perceive the benefits of Nimbus-based versus conventional monopolar radiofrequency techniques over time.
One of the specific aims of COBRA-SIJ is to compare the proportions of participants reporting improved or much improved PGIC ratings between the N‑SIJRFA and C‑SIJRFA groups. This comparison is intended to complement more quantitative measures such as NPRS, ODI, and EQ‑5D by integrating the patient’s holistic assessment of treatment impact. Because PGIC inherently reflects the patient’s synthesis of pain relief, functional change, and side effects, it serves as a pragmatic indicator of satisfaction with sacroiliac radiofrequency and can be particularly informative when counseling patients about what to expect after the procedure.
The protocol also plans to examine satisfaction in relation to the degree of pain relief achieved after diagnostic or prognostic interventions. Specifically, COBRA-SIJ will evaluate differences in success rates for pain improvement, functional improvement, and satisfaction among participants who experience 50% or greater, 80% or greater, or 100% pain relief after posterior sacral network blocks or intra-articular sacroiliac joint injections. By linking PGIC outcomes to these pre‑ablation responses, the study aims to clarify how initial analgesic responses may predict subsequent satisfaction with sacroiliac radiofrequency, which is relevant for patient selection and expectation management.
PGIC findings in COBRA-SIJ are interpreted alongside other secondary outcomes, including pain-related sleep disturbance measured by the Pain and Sleep Questionnaire (PSQ‑3), adverse event rates, and subsequent interventional health care utilization such as repeat radiofrequency ablation, sacroiliac joint injections, or fusion procedures. This integrated outcome set allows investigators to contextualize patient satisfaction within a broader clinical picture, including durability of benefit and the need for additional interventions. In this way, PGIC contributes to a comprehensive understanding of patient-centered outcomes after sacroiliac radiofrequency ablation.
Outcome timeline: 3 to 24 months
The COBRA-SIJ trial is structured around a 24‑month follow-up period after sacroiliac radiofrequency ablation, with key outcome assessments at 3, 6, 12, 18, and 24 months. The three‑month time point serves as the primary endpoint for pain relief, defined as the proportion of participants achieving at least a 50% reduction in NPRS compared with baseline. This early assessment is chosen to capture the initial clinical response to posterior sacral network ablation using either Nimbus-based bipolar palisade lesions or conventional monopolar periforaminal lesions.
Beyond three months, the trial emphasizes durability of effect. Secondary outcomes include the proportions of participants with 50% or greater NPRS pain relief at 6, 12, 18, and 24 months, as well as the proportions achieving 15‑point or greater reductions in ODI and clinically significant (0.03 or greater) improvements in EQ‑5D at the same intervals. PGIC ratings and PSQ‑3 scores are also collected at each follow-up, enabling a multidimensional assessment of pain, function, quality of life, sleep, and global improvement over two years. This repeated-measures design is intended to delineate the trajectory of clinical outcomes after sacroiliac radiofrequency rather than relying on a single time point.
The protocol further incorporates time-to-event analyses to characterize the persistence of treatment success. Time to failure is defined as either the return of at least 50% of the index pain or the need for repeat sacroiliac radiofrequency ablation. Survival analyses will be used to illustrate the percentage of patients in each treatment group who maintain 50% or greater pain relief without additional interventional health care utilization, such as repeat radiofrequency, sacroiliac joint injections, or fusion procedures, over the 24‑month follow-up. This approach provides a clinically intuitive depiction of how long patients can expect to sustain meaningful benefit after sacroiliac radiofrequency.
The 24‑month horizon of COBRA-SIJ is also reflected in the overall study duration specified in regulatory documentation, which notes a total study duration of 24 months from the day of the procedure. Within this timeframe, the investigators plan to complete enrollment, perform the randomized interventions, and collect all scheduled outcome data. By aligning the follow-up schedule with this two‑year window, the trial aims to provide a comprehensive description of medium‑term outcomes after sacroiliac radiofrequency, including patterns of pain relief, functional change, patient satisfaction, sleep disturbance, adverse events, and subsequent interventional care.
Evidence from COBRA-SIJ study
The COBRA-SIJ study is a double-blind, randomized, comparative trial designed to evaluate conventional versus bipolar radiofrequency ablation for the treatment of sacroiliac joint pain. Participants with chronic low back pain attributable to the sacroiliac joint complex, confirmed by physical examination, imaging, and prognostic posterior sacral network or diagnostic intra-articular sacroiliac joint blocks, are randomized to receive either Nimbus-based bipolar palisade lesions (N‑SIJRFA) or conventional monopolar periforaminal lesions (C‑SIJRFA). The central hypothesis is that N‑SIJRFA will be more effective than C‑SIJRFA in improving pain and function at 3, 6, 12, 18, and 24 months.
The rationale for comparing these two techniques is grounded in cadaveric work demonstrating that large bipolar strip lesions can achieve very high rates of posterior sacral network neural capture, whereas conventional monopolar periforaminal lesions may capture only a small fraction of the network. Nimbus is a multi‑tined radiofrequency probe that produces large bipolar lesions and is therefore considered an attractive option for more complete posterior sacral network ablation. Both Nimbus-based and conventional techniques are already in clinical use, but prior to COBRA-SIJ there were no prospective randomized controlled trials directly comparing their clinical outcomes in sacroiliac joint complex pain.
COBRA-SIJ specifies a comprehensive set of specific aims that collectively define its outcome framework. These include comparing the proportions of participants achieving 50% or greater NPRS pain relief, 15‑point or greater ODI reductions, and clinically significant (0.03 or greater) EQ‑5D improvements between N‑SIJRFA and C‑SIJRFA, as well as comparing the proportions reporting improved or much improved PGIC ratings. Additional aims include evaluating differences in success rates for pain, function, and satisfaction across strata of prognostic block response, assessing the effect of posterior sacral network ablation on pain-related sleep disturbance, comparing procedural time requirements, and reporting adverse effects and subsequent interventional health care utilization.
The study’s significance statement emphasizes that COBRA-SIJ is intended to address a major knowledge gap regarding the impact of complete posterior sacral network ablation via Nimbus-based radiofrequency on clinical outcomes in sacroiliac joint complex pain. By using a rigorous randomized, double-blind design and standardized outcome measures over a 24‑month follow-up, the trial aims to clarify whether more extensive neural capture with bipolar palisade lesions translates into superior pain relief, functional improvement, and patient satisfaction compared with conventional monopolar periforaminal techniques. The results are expected to inform the treatment paradigm for sacroiliac radiofrequency and to support a more standardized approach to posterior sacral network neurotomy in clinical practice.
Sources (Bibliography)
- Conger A, McCormick Z, Kendall R, Wagner G, Burnham T. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blind, Randomized, Comparative Trial, Version 3.0, 03 January 2023.
- Conger A, McCormick Z, Kendall R, Wagner G, Burnham T. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blind, Randomized, Comparative Trial, Investigational Testing Authorization Form, 2024.
- D W Lee, S Pritzlaff, M J Jung, P Ghosh, J M Hagedorn, J Tate, K Scarfo, N Strand, K Chakravarthy, D Sayed, T R Deer, K Amirdelfan, Latest Evidence Based Application for Radiofrequency Neurotomy, Journal of Pain Research 2021:14 2807–2831.